The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade).

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Abstract Text:

R M Auty,

Nedocromil sodium is the disodium salt of a novel pyranoquinoline dicarboxylic acid which has physicochemical and pharmacokinetic properties which make it suitable for delivery to the respiratory tract by inhalation. Its biological properties suggest that it will display anti-allergic effects in man and that it will also have anti-inflammatory activity in chronic reversible obstructive airways disease. The clinical development of nedocromil sodium has been influenced by its anticipated effects in man and also by the knowledge that preclinical and early clinical tests are poor predictors of efficacy for agents of this type. Thus, although nedocromil sodium prevents immediate and delayed reactions to bronchial antigen challenge, and also prevents exercise-induced bronchoconstriction, the clinical development programme of this drug was designed to provide therapeutic double-blind trials of 1 month's treatment with the drug at the earliest opportunity, because this was thought to be the definitive test for activity. Studies on a larger scale and of longer duration followed the positive outcome of the first therapeutic trials. This series of studies, conducted to different designs, demonstrated the safety and efficacy of nedocromil sodium. They also permitted a view to be gained of the place of nedocromil sodium in the management of patients with airways inflammation.

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Publishing Authors By Initials

RM Auty,

For similar respiratory tract diseases research abstracts see: respiratory tract diseases research

PUBMED ID PMID:

MEDLINE DATE:

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of respiratory diseases. Suppleme

VOLUME: 147

Page Numbers: 120-31

Journal Abbreviation:

ISSN: 0106-4347

DAY: 21

MONTH: 02

YEAR: 1986

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8010618

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Keywords Mesh Terms:

KEYWORDS: Respiratory Tract Diseases

MESH TERMS: drug therapy

Chemical & Substance for Abstract: The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade). Information

Substance Name: Nedocromil

Registry Number: 69049-73-6

Grant and Affiliation Information for The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade).

AFFILIATION:

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Respir Dis Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium Tilade Related Publications

• Dermal metastases from a follicular carcinoma of the thyroid.
• Disposable tray for soaking membranes for Kiil dialysers.
• Fermentative production of hydrogen from a wheat flour industry co-product.
• The clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade).